Targeting the pathophysiology of type 2 diabetes: Rationale for combination therapy with pioglitazone and exenatide

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3009-3022

  Schwartz, Stanley ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Dyslipidemias; Glucagon like peptide 1; Hypoglycemia; Pancreatic beta cells; Thiazolidinediones

Indexed keywords

ALOGLIPTIN; EXENDIN 4; GLARGINE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BODY WEIGHT; CELL FUNCTION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STROKE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

ALGORITHMS; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR TARGETED THERAPY; PEPTIDES; RATIONALIZATION; THIAZOLIDINEDIONES; VENOMS;

EID: 67649415112     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802390795     Document Type: Review

References (122)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 (UKPDS 33). Lancet 1998;352:837-853
2. Stratton IM, Adler AT, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-412 (Pubitemid 30609442)
3. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559
4. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
5. Duckworth W, for the VADT Study Group. Results of the VA Diabetes Trial. Presented at the 68th Annual Meeting of the American Diabetes Association. San Francisco, CA, June 8, 2008
6. Schneider CA. Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control. Curr Med Res Opin 2006;22(Suppl. 2):S15-S26 (Pubitemid 44435116)
7. Das SK, Elbein SC. The genetic basis of type 2 diabetes. Cell Science 2006;2:100-131
8. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787-794 (Pubitemid 29536364)
9. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444:840-846 (Pubitemid 46024990)
10. Müller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-115
11. Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 2004;17:183-190
12. Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and implications. Clin Ther 2005; 27(Suppl. B):S42-S56
13. Hanefeld M, Koehler C, Fuecker K, et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003;26:868-874 (Pubitemid 36929357)
14. Genuth S, Kahn R. A step backward - or is it forward? Diabetes Care 2008;31:1093-1096
15. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003;26:881-885
16. Barr ELM, Boyko EJ, Zimmet PZ, et al. Two-hour glucose predicts the development of hypertension over five years: the AusDiab study. 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD). Amsterdam, The Netherlands, September 13-17, 2007 [abstract 290]
17. DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405 (Pubitemid 32116556)
18. Brindisi MC, Rabasa-Lhoret R, Chiasson JL. Postprandial hyperglycemia: to treat or not to treat? Diabetes Metab 2006; 32:105-111
19. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63:492-498 (Pubitemid 16035703)
20. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006;6:194-201 (Pubitemid 43918645)
21. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 (Pubitemid 46048557)
22. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520 (Pubitemid 28084232)
23. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997;160:413-422 (Pubitemid 27342031)
24. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744 (Pubitemid 23218642)
25. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-1553
26. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-2940 (Pubitemid 37205571)
27. Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144:2242-2252 (Pubitemid 36629873)
28. Program for the Management of Diabetes, University of Pennsylvania Health System Intranet, updated 2007. http:// uphsxnet.uphs.upenn.edu/ceqi/clininfo/ outpa/diabetes.html [accessed January 2008]
29. Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 2006;10:349-360 (Pubitemid 44546687)
30. Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003;17:662-676 (Pubitemid 36403578)
31. Goldberg RB, Kendall DM, Deeg MA, et al. For the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554
32. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. J Am Med Assoc 2007;298:1189-1195 (Pubitemid 47403105)
33. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 2007; 298:1180-1188 (Pubitemid 47403104)
34. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
35. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-372 (Pubitemid 34256388)
36. Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006;15:243-250 (Pubitemid 43338145)
37. Patel CB, De LemosJA, Wyne KL, et al. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR gamma agonism. Diab Vasc Dis Res 2006;3:65-71 (Pubitemid 44638378)
38. Göke B, Lübben G, Bates P, on behalf of the German Pioglitazone Study Group. Coefficient of β-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. Exp Clin Endocrinol Diabetes 2004;112:115-117
39. Füllert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87:5503-5506 (Pubitemid 36034352)
40. Rosenblatt S, Miskin B, Glazer NB, et al., for the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-423
41. Mohanty P, Aliada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-2735 (Pubitemid 38766357)
42. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684 (Pubitemid 34851926)
43. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107:1954-1957 (Pubitemid 36506065)
44. Deeg MA, Buse JB, Goldberg RB, et al., for the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-2464 [epub 2007 June 26]
45. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581 (Pubitemid 44903861)
46. Steg PG, Marre M. Does PERISCOPE provide a new perspective on diabetic treatment? J Am Med Assoc 2008;299:1603-1604
47. Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs 2006;6:297-304 (Pubitemid 44749339)
48. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307 (Pubitemid 44837778)
49. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagonlike peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215 (Pubitemid 39491964)
50. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide- 1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699 (Pubitemid 44881367)
51. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006;49:452-458 (Pubitemid 43277867)
52. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon- like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110:955-961 (Pubitemid 39128621)
53. Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagonlike peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-1113 (Pubitemid 43764114)
54. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-1135 (Pubitemid 36667866)
55. Thrainsdottir I, Malmberg K, Olsson A, et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004;1:40-43
56. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3:159-165 (Pubitemid 44902481)
57. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidylpeptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-180 (Pubitemid 46269371)
58. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the DPP-4 inhibitor sitagliptin and pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-1568 (Pubitemid 44841980)
59. Stein PP, Williams-Herman D, Khatami H, et al. Sitagliptin, a selective DPP-4 inhibitor, is well tolerated in patients with type 2 diabetes: pooled analysis of 5141 patients in clinical trials for up to 2 years. 67th Scientific Sessions of the American Diabetes Association. Chicago, Illinois, June 22-26, 2007 [poster 534-P]
60. Januvia [prescribing information]. Whitehouse Station (NJ): Merck & Co., Inc.; 2007
61. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-2104 (Pubitemid 39419498)
62. Khan M, Xu Y, Edwards G, et al. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomized studies. Int J Clin Pract 2004;58:907-912 (Pubitemid 39642610)
63. Chappuis B, Braun M, Stettler C, et al. Differential effects of pioglitazone and rosiglitazone on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23:392-399 (Pubitemid 47091243)
64. Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;3:39-44 (Pubitemid 43877252)
65. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized, controlled trial. Lancet 2005;366:1279-1289 (Pubitemid 41416583)
66. Wilcox R, Bousser MG, Betteridge D, for the PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-873
67. Erdmann E, Wilcox R, Perez A, et al. Mortality after serious heart failure: results from PROactive. J Am Coll Cardiol 2007;(Suppl.):66A [abstract 1016-65]
68. Macfarlane DP, Paterson KR, Fisher M. Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab 2007;9:23-30 (Pubitemid 44921038)
69. Donnelly R. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. Int J Clin Pract 2007;61:1160-1169 (Pubitemid 46934622)
70. Deeks ED, Keam SJ. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs 2007;67:2747-2779 (Pubitemid 350224383)
71. Erdmann E, Dormandy JA, Charbonnel B, et al. For the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007;49:1772-1780 (Pubitemid 46629127)
72. Irons BK, Greene RS, Mazzolini TA, et al. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 2006;26:168-181 (Pubitemid 43201866)
73. Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc 2008;83:333-342
74. Araki T, Emoto M, Teramura M, et al. Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin. Metab Clin Exp 2006; 55:996-1001 (Pubitemid 44026543)
75. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792 (Pubitemid 44033298)
76. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111: 2525-2531 (Pubitemid 40696142)
77. Hodis HN, Mack WJ, LeBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262-269 (Pubitemid 28090756)
78. Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
79. Nissen SE; PERISCOPE Investigators. Effect of pioglitazone versus glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. Presented at the 57th annual Scientific Session of the American College of Cardiology. March 31, 2008. Presentation number 407-413
80. Rosen CJ. The rosiglitazone story - lessons from an FDA advisory committee meeting. N Engl J Med 2007;357:844-846 (Pubitemid 47347317)
81. Gerrits CM, Bhatacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16:1314-1316 (Pubitemid 350303445)
82. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-2643 (Pubitemid 350254955)
83. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38 (Pubitemid 47026732)
84. Avandia [prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; August 2007
85. GlaxoSmithKline. Avandia cardiovascular event modeling project study No.: HM2006/00497/00/WEUSRTP866: coronary heart disease outcomes in patients receiving antidiabetic agents [study No.: ZM2005/00181/01]. Available at http://ctr.gsk. co.uk/Summary/Rosiglitazone/III-CVmodeling.pdf [accessed May 5, 2008]
86. European Medicines Agency. EMEA recommends new warnings and contraindications for rosiglitazone [press release]. Available at http://www.emea.europa.eu/humandocs/PDFs/ EPAR/avaglim/4223208en.pdf [accessed May 5, 2008]
87. GlaxoSmithKline. Health Canada endorsed important safety information on rosiglitazone [public communication]. Available at http://www.hc-sc.gc.ca/dhp- mps/alt-formats/ hpfb-dgpsa/pdf/medeff/avandia-pc-cp-4-e.pdf [accessed May 5, 2008]
88. ACTOS [prescribing information]. Deerfield (IL): Takeda Pharmaceuticals America, Inc.; September 2007
89. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89:1140-1145 (Pubitemid 38368402)
90. Guan YF, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPAR-gamma stimulation of EnaC-mediated renal sodium absorption. Nat Med 2005; 11:861-866 (Pubitemid 41161118)
91. Tang WH. Do thiazolidinediones cause heart failure? A critical review. Cleve Clin J Med 2006;73:390-397
92. Erdmann E, Charbonnel B, Wilcox RG, et al. On behalf of the PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-2778
93. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136 (Pubitemid 47464583)
94. GlaxoSmithKline. Dear Healthcare professional letter re: clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus, February 2007. Available at http://www.fda.gov/ MedWatch/SAFETY/2007/Avandia-GSK-Ltr.pdf [accessed July 29, 2008]
95. Takeda Pharmaceuticals, Inc. Dear Healthcare professional letter re: observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus, March 2007. Available at http://www.fda.gov/medwatch/ safety/2007/Actosmar0807.pdf [accessed July 29, 2008]
96. Efficacy study of pioglitazone HCL on bone metabolism in postmenopausal women with impaired fasting glucose. Available at http://www.clinicaltrials.gov/ ct2/show/NCT00708175? term=pioglitazone&rank=1 [accessed July 28, 2008]
97. Study in postmenopausal women with type 2 diabetes looking at approved diabetes drugs and how they affect bone health. Available at http://www.clinicaltrials.gov/ct2/ show/NCT00679939?term= rosiglitazone+and+bone&rank=2 [accessed July 28, 2008]
98. Barnett AH. Insulin-sensitizing agents - thiazolidinediones (glitazones). Curr Med Res Opin 2002;18(Suppl. 1):S31-S39
99. Scheen AJ. Glitazones and weight gain. Ann Endocrinol (Paris) 2002;63:IS412-IS414
100. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62:1463-1480 (Pubitemid 34804155)
101. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000; 22:1395-1409 (Pubitemid 32056079)
102. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702 (Pubitemid 30196209)
103. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47:159-169 (Pubitemid 28079969)
104. Nauck MA, Duran S, Kim D, et al. A comparison of twicedaily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50:259-267
105. Heine RJ, Van GaalLF, Johns D, et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
106. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin- 4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089 (Pubitemid 36877476)
107. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100 (Pubitemid 40616618)
108. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091 (Pubitemid 40616617)
109. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-1493 (Pubitemid 46871159)
110. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm 2005; 62:173-181 (Pubitemid 40674548)
111. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447 (Pubitemid 44349236)
112. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-5997 (Pubitemid 41606516)
113. Buse JB, Henry RR, Han J, et al., for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635
114. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29:139-153 (Pubitemid 46414034)
115. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286 (Pubitemid 351160260)
116. Kendall DM, Kim D, Poon T, et al. Improvements in cardiovascular risk factors accompanied improved glycemic control and weight reduction in patients with type 2 diabetes treated with exenatide for 3.5 years. 67th Scientific Sessions of the American Diabetes Association. Chicago, Illinois, June 22-26, 2007 [poster 557-P]
117. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-485 (Pubitemid 351650556)
118. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096-1105
119. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803 (Pubitemid 34970933)
120. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
121. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077 (Pubitemid 34680970)
122. DeFronzo F. Results of the ACTos NOW for the Prevention of Diabetes Study (ACTNOW). Presented at the 68th Annual Meeting of the American Diabetes Association. San Francisco, CA, June 8, 2008